Goldman Sachs: Gilead Sciences, Inc. (NASDAQ:GILD) Is A Stock With High Consensus ROE
Gilead to Withdraw U.S. Accelerated Approval for Trodelvy in Metastatic Urothelial Cancer
Express News | Gilead Shares Down 1% Premarket After Co to Voluntarily Withdraw Urothelial Cancer Drug in U.S.
Express News | Gilead: To Voluntarily Withdraw U.S. Accelerated Approval for Trodelvy for Treatment of Adults With Locally Advanced/Metastatic Urothelial Cancer
Here's How Much $100 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today
Bernstein: First coverage of eli lilly and co, gilead sciences, and amgen all rated as "outperforming the large cap".
Bernstein initiated coverage on eli lilly and co, gilead sciences, and amgen, all with an 'outperform' rating. Bernstein stated that the bullish rating on gilead and amgen is based on optimistic expectations for key assets to achieve revenue growth from now until 2030, including gilead's HIV PreEP treatment lenacapavir, amgen's weight loss drug MariTide, and rare disease investment portfolio. As for eli lilly and co, Bernstein stated that the rating "depends on how it leverages the cash obtained from weight loss drugs", eli lilly and co is ready to use a diversified investment portfolio and leverage weight loss drugs for growth. In addition, Bern
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}